Clinical Manifestations and Treatments of Ocular Toxoplasmosis
Main Article Content
Keywords
toxoplasmosis, ocular, parasite, necrotizing retinitis
Abstract
Ocular toxoplasmosis is a progressive necrotizing retinitis caused by the protozoan parasite Toxoplasma gondii. Infection may be congenital or acquired through ingestion of uncooked meat, contaminated vegetables or water. A focal fluffy white lesion with necrotizing retinitis or retinochoroiditis adjacent to a variably pigmented chorioretinal scar are the common typical findings. Imaging of the retina and serology test can be helpful in confirming ocular toxoplasmosis. Treatment aimed at reducing the severity of the disease by halting parasite replication thus minimizing the lesion size. Multiple drugs combinations of antibiotics and corticosteroids are needed to prevent vision loss. Beside the classic “triple-drug therapy”, combination of trimethoprim-sulfamethoxazole and corticosteroid or intravitreal injection of clindamycin are tolerable alternatives to pyrimethamine-sulfadiazine.
References
2. Maenz M, Schlüter D, Liesenfeld O, Schares G, Gross U, Pleyer U. Ocular toxoplasmosis past, present and new aspects of an old disease. Prog Retin Eye Res. 2014;39:77-106. DOI:10.1016/j.preteyeres.2013.12.005
3. McCannel CA, Holland GN, Helm CJ, Cornell PJ, Winston JV, Rimmer TG. Causes of uveitis in the general practice of ophthalmology. UCLA Community-Based Uveitis Study Group. Am J Ophthalmol. 1996;121(1):35-46. DOI:10.1016/s0002-9394(14)70532-x
4. Soheilian M, Heidari K, Yazdani S, Shahsavari M, Ahmadieh H, Dehghan M. Patterns of uveitis in a tertiary eye care center in Iran. Ocul Immunol Inflamm. 2004;12(4):297-310. DOI:10.1080/092739490500174
5. Robert-Gangneux F, Dardé ML. Epidemiology and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev. 2012;25(2):264-296. DOI:10.1128/CMR.05013-11
6. Ozgonul C, Besirli C, G: Recent Developments in the Diagnosis and Treatment of Ocular Toxoplasmosis. Ophthalmic Res. 2017;57:1-12. DOI: 10.1159/000449169
7. Lune AA, Pujari SN, Lune SA. Ocular toxoplasmosis: A case report with review of literature. Med J DY Patil Univ. 2014;7:818-21. DOI:10.4103/0975-2870.144900
8. Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans. Int J Parasitol. 2000;30(12-13):1217-1258. DOI:10.1016/s0020-7519(00)00124-7
9. Nida Sen H, et al. Basic and Clinical Science Course Section 9: Uveitis and Intraocular Inflammation. San Fransisco: American Academy of Ophthalmology; 2019. Chapter 11, Infectious Uveitis: Nonbacterial Causes; p.207-317.
10. Pleyer U, Schlüter D, Mänz M: Ocular Toxoplasmosis: Recent Aspects of Pathophysiology and Clinical Implications. Ophthalmic Res. 2014;52:116-123. DOI: 10.1159/000363141
11. Silveira C, Vallochi AL, Rodrigues da Silva U, et al. Toxoplasma gondii in the peripheral blood of patients with acute and chronic toxoplasmosis. Br J Ophthalmol. 2011;95(3):396-400. DOI:10.1136/bjo.2008.148205
12. Pavesio CE, Lightman S. Toxoplasma gondii and ocular toxoplasmosis: pathogenesis. British Journal of Ophthalmology. 1996;80:1099-1107. DOI:10.1136/bjo.80.12.1099
13. Delair E, Latkany P, Noble AG, Rabiah P, McLeod R, Brézin A. Clinical manifestations of ocular toxoplasmosis. Ocul Immunol Inflamm. 2011;19(2):91-102. DOI:10.3109/09273948.2011.564068
14. Butler NJ, Furtado JM, Winthrop, KL, Smith JR. Ocular toxoplasmosis II: clinical features, pathology and management. Clinical & Experimental Ophthalmology. 2014;41:95-108. DOI:10.1111/j.1442-9071.2012.02838.x
15. Park YH, Nam HW. Clinical features and treatment of ocular toxoplasmosis. Korean J Parasitol. 2013;51(4):393-399. DOI:10.3347/kjp.2013.51.4.393
16. Goldenberg D, Goldstein M, Loewenstein A, Habot-Wilner Z. Vitreal, retinal, and choroidal findings in active and scarred toxoplasmosis lesions: a prospective study by spectral-domain optical coherence tomography. Graefes Arch Clin Exp Ophthalmol. 2013;251(8):2037-2045. DOI:10.1007/s00417-013-2334-3
17. Freitas-Neto CA, Cao JH, Oréfice JL, et al. Increased Submacular Choroidal Thickness in Active, Isolated, Extramacular Toxoplasmosis. Ophthalmology. 2016;123(1):222-4.e1. DOI:10.1016/j.ophtha.2015.06.045
18. Ghavidel LA, Milani AE, Bagheri M. Comparison of Azithromycin and Pyrimethamine/ Sulfadiazine Treatment in Ocular Toxoplasmosis in North West of Iran. Crescent Journal of Medical and Biological Sciences. 2017;4(2):80–84. [Available from https://www.cjmb.org]
19. Soheilian M, Ramezani A, Azimzadeh A, et al. Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology. 2011;118(1):134-141. DOI:10.1016/j.ophtha.2010.04.020
20. Montoya JG, Remington JS. Management of Toxoplasma gondii infection during pregnancy. Clin Infect Dis. 2008;47(4):554-566. DOI:10.1086/590149
21. Bosch-Driessen LE, Berendschot TT, Ongkosuwito JV, Rothova A. Ocular toxoplasmosis: clinical features and prognosis of 154 patients. Ophthalmology. 2002;109(5):869-878. DOI:10.1016/s0161-6420(02)00990-9